1. Home
  2. CTKB vs PRTA Comparison

CTKB vs PRTA Comparison

Compare CTKB & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cytek Biosciences Inc.

CTKB

Cytek Biosciences Inc.

HOLD

Current Price

$4.17

Market Cap

652.1M

Sector

Health Care

ML Signal

HOLD

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$8.85

Market Cap

538.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTKB
PRTA
Founded
1990
2012
Country
United States
Ireland
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
652.1M
538.3M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
CTKB
PRTA
Price
$4.17
$8.85
Analyst Decision
Hold
Buy
Analyst Count
5
9
Target Price
$5.70
$18.86
AVG Volume (30 Days)
890.3K
475.3K
Earning Date
02-25-2026
02-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$196,828,000.00
$11,786,000.00
Revenue This Year
$0.15
N/A
Revenue Next Year
$5.20
$1,183.79
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.37
$4.32
52 Week High
$6.18
$16.67

Technical Indicators

Market Signals
Indicator
CTKB
PRTA
Relative Strength Index (RSI) 27.05 44.89
Support Level $4.86 $8.65
Resistance Level $5.29 $9.12
Average True Range (ATR) 0.24 0.49
MACD -0.11 -0.01
Stochastic Oscillator 6.22 32.02

Price Performance

Historical Comparison
CTKB
PRTA

About CTKB Cytek Biosciences Inc.

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

Share on Social Networks: